Recombinant DNA News and Research

RSS

Recombinant DNA is a variety of techniques that molecular biologists use to manipulate DNA molecules to study the expression of a gene.

Experts offer research strategies to yield more protective flu vaccine candidates

In a New England Journal of Medicine perspective, experts from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the World Health Organization Collaborating Centre for Reference and Research on Influenza in Melbourne discuss how the process of preparing seasonal influenza vaccines in eggs may contribute to their limited effectiveness.

30 Nov 2017

Scientists build DNA from scratch using yeast

Researchers are rewriting the yeast genome from scratch as part of a controversial project aiming to create custom-made chunks of DNA codes. One goal of the project is to create codes that can be inserted into cells to alter their function or even improve drug development.

26 Jul 2017

Molecule discovered in worm spit could offer solution for non-healing wounds

Every day 12 Australian diabetics have a limb amputated because of a non-healing wound. Globally, it's one every 30 seconds.

25 May 2017

Penn researcher receives $16.3 million NIAID grant to develop long-sought-after HIV vaccine

Building on earlier work in designing chimeric human-simian immunodeficiency viruses (SHIVs) that serve as a model of HIV infection of humans, George M. Shaw, MD, PhD, a professor of Hematology/Oncology and Microbiology in the Perelman School of Medicine at the University of Pennsylvania, has received $16.3 million over five years from the National Institute of Allergy and Infectious Diseases to develop a long-sought-after HIV vaccine.

22 Mar 2017

Mussels inspire scientists to attach biologically active molecule to titanium surface

Titanium is used medically in applications such as artificial joints and dental implants. While it is strong and is not harmful to tissues, the metal lacks some of the beneficial biological properties of natural tissues such as bones and natural teeth.

11 Jul 2016

SIPPET study may have implications for treatment of patients with severe hemophilia A

SIPPET, a study which involved 42 centers in 14 countries in Europe, North and South America, Africa and Asia was designed to definitively settle the long-debated question whether factor VIII concentrates from different sources (plasma-derived containing VWF or recombinant technology) differ in risk of inhibitor development in previously untreated children (PUPs) with severe hemophilia A.

28 May 2016

Cinqair (reslizumab) approved for treatment of severe asthma

The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.

23 Mar 2016

Idelvion approved for use in children and adults with Hemophilia B

The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.

7 Mar 2016

Study highlights new approach to produce coral snake antivenom from synthetically designed DNA

Coral snake venom carries significant neurotoxicity and human injuries can be severe or even lethal. Despite this, antivenom treatments are scarce due to challenges collecting adequate amounts of venom needed to produce anti-elapidic serum. PLOS Neglected Tropical Diseases highlights exciting new research from the Butantan Institute in Brazil using synthetically designed DNA to produce coral-snake antivenom.

4 Mar 2016

Regrowing dopaminergic neurons may lead to new therapy for Parkinson's disease

While scientists are unsure of the molecular causes of Parkinson's Disease, they do know the disorder's tremors and other motor dysfunctions are linked to a loss of dopaminergic neurons located in the substantia nigra, a structure in the midbrain.

16 Feb 2016

2D-NMR could be a powerful complementary technique for assessing biosimilarity of protein drugs

A first-ever interlaboratory study of four versions of a therapeutic protein drug—all manufactured from living cells—reports that an established analytical tool akin to magnetic resonance imaging reliably assessed the atomic structures of the biologically similar products, yielding the equivalent of a fingerprint for each.

10 Feb 2016

FDA clears Sangamo BioSciences' SB-318 IND application for treatment of MPS I

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I).

8 Feb 2016

Kanuma approved as first treatment for patients with LAL deficiency

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.

8 Dec 2015

FDA takes important steps regarding genetically engineered plants and animals intended for food

Based on sound science and a comprehensive review, the U.S. Food and Drug Administration is taking several important steps today regarding food from genetically engineered (GE) plants and animals, including the first approval for a genetically engineered animal intended for food, AquAdvantage Salmon.

20 Nov 2015

Researchers devise system to accelerate the process of making life-saving vaccines

Researchers at Brigham Young University have devised a system to speed up the process of making life-saving vaccines for new viruses.

20 Nov 2015

Nucala (mepolizumab) approved for treatment of asthma patients

The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.

5 Nov 2015

Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines, today announced that it has entered a collaboration with German biotechnology company Cilian AG to develop a solid dose formulation of Cilian's experimental recombinant influenza vaccine, CiFlu, for delivery using Glide's patient-friendly SDI delivery device.

21 Sep 2015

TGen and Baylor partnership set to increase treatment options for cancer patients

The Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) at Dallas today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.

22 May 2015

NAS, NAM launch major initiative to guide decision making on human gene-editing research

The National Academy of Sciences and the National Academy of Medicine are launching a major initiative to guide decision making about controversial new research involving human gene editing. Human gene-editing technologies, such as CRISPR-Cas9, may lead to promising new treatments for disease.

19 May 2015

Scientists develop potential new therapy based on cow's immune molecules for hormone deficiencies

To help people with hormone deficiencies, scientists at The Scripps Research Institute have developed a potential new therapy based on an unlikely model: immune molecules from cows.

9 Feb 2015